References
- Tidy JA, Gillespie AM, Bright N, Radstone CR, Coleman RE, Hancock BW. Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy. Gynecol Oncol 78(3 Pt 1), 309–312 (2000).
- •Large retrospective study looking at the changes in the mode of evacuation over two time periods but also going on to show that suction curettage is a safer method of evacuation compared with medical methods in terms of the need for future chemotherapy.
- Seckl MJ, Newlands ES. Treatment of gestational trophoblastic disease. Genet. Diagn. Pallid. 143(2–3), 159–171 (1997).
- Hammond CB, Borchert LG, Tyrey L, Creasman WT, Parker RE Treatment of metastatic trophoblastic disease: good and poor prognosis. Am. J. Obstet. Gynecol 115(4), 451–457 (1973).
- Bagshawe KD. Risk and prognostic factors in trophoblastic neoplasia. Cancer 38(3), 1373–1385 (1976).
- Kohorn El. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment. Int. J. Gynecol Cancer11(1), 73–77 (2001).
- •• Excellent discussion on the proposed new FIGO staging and scoring system incorporating both the requirements needed to diagnose and Stage GTD as well as the weaknesses of the new system.
- Hancock BVV, Welch EM, Gillespie AM, Newlands ES. A retrospective comparison of current and proposed staging and scoring systems for persistent gestational trophoblastic disease. Lit. j Gynecol Cancer 10(4), 318–322 (2000).
- ••Retrospective study showing thesimilarities between the various staging/ scoring systems and highlighting the fact that patients can be safely divided into only low- and high-risk. The suitability of the proposed FIGO staging/scoring system is also assessed.
- Matsui H, Iitsuka Y, Seki K, Sekiya S. Comparison of chemotherapies with methotrexate, VP-16 and actinomycin-D in low-risk gestational trophoblastic disease. Remission rates and drug toxicities. Gynecol Obstet. Invest. 46(1), 5–8 (1998).
- Dobson LS, Lorigan PC, Coleman RE, Hancock BW. Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease. Br. Cancer 82(9), 1547–1552 (2000).
- ••Large retrospective analysis outlining treatment of methotrexate-resistant gestational trophoblastic disease (GTD) and high-risk GTD with MEA (methotrexate, etoposide and actinomycin D) chemotherapy. A good appraisal of the toxicities of the regime together with a comparison of treatments at Charing Cross Hospital, London, UK and the USA.
- McNeish IA, Strickland L, Holden et al Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000.. Clin. Oncol 20(7), 1838–1844 (2002)
- Bower M, Newlands ES, Holden L et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. Clin. Oncol 15(7), 2636–2643 (1997).
- ••Comprehensive analysis of outcomes anddifficulties treating patients with high-risk disease. Also highlights particular additional adverse features in certain patient groups.
- Matsui H, Suzuka K, Iitsuka Y, Seki K, Sekiya S. Combination chemotherapy with methotrexate, etoposide and actinomycin D for high-risk gestational trophoblastic tumors. Gynecol Oncol 78(1), 28–31 (2000).
- Newlands ES, Mulholland PJ, Holden L, Seckl MJ, Rustin GJ. Etoposide and cisplatin/etoposide, methotrexate and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/ cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. f. Cliii. Oncol. 18(4)854-859 (2000).
- •Recent review of chemotherapy treatment for refractory disease including a discussion on the role of surgery and its future appplication.
- Rustin GJ, Newlands ES, Lutz JM et Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. j Cliii. Oncol. 14(10), 2769–2773 (1996).
- Schorge JO, Goldstein DP, Bernstein MR, Berkowitz RS. Recent advances in gestational trophoblastic disease. j Reprod. Med. 45(9), 692–700 (2000).
- •Informative overview of GTD looking in particular at treatment and its long-term sequel.